Where is Immunovant (IMVT) Heading According to Analysts?

Immunovant, Inc. (NASDAQ:IMVT) is one of the best strong buy stocks to invest in according to Wall Street. On September 3, LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant, Inc. (NASDAQ:IMVT), keeping the price target at $50.00.

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings?

Similarly, BofA analyst Jason Gerberry maintained a buy rating on the stock but lowered the firm’s price target on Immunovant, Inc. (NASDAQ:IMVT) to $30 from $33.

Leerink Partners analyst Thomas Smith also expressed bullish sentiments for Immunovant, Inc. (NASDAQ:IMVT), reiterating a Buy rating with a $52.00 price target.

The analyst consensus rating for Immunovant, Inc. (NASDAQ:IMVT) is a Strong Buy, and the stock’s median price target of $16.23 implies an upside of 174.18% from current levels.

Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402. Both are novel antibodies targeting the neonatal fragment crystallizable receptor (FcRn).

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.